Mission Statement, Vision, & Core Values of Neuronetics, Inc. (STIM)

Are you curious about what drives a company like Neuronetics, Inc. (STIM), especially with their reported total revenue of $84.9 million for the year 2024?

Understanding a company's mission, vision, and core values offers a glimpse into its strategic objectives and operational philosophy. But how do these elements translate into real-world impact, and what do they mean for stakeholders like investors and patients?

Dive in to explore how Neuronetics' guiding principles shape its approach to neurohealth and its commitment to improving patient outcomes, all while navigating the complexities of the medical technology market.

Neuronetics, Inc. (STIM) An Overview of

Neuronetics, Inc. (STIM) is a commercial stage medical device company focused on developing and marketing innovative, non-invasive treatments for psychiatric disorders. Founded in 2003, the company is headquartered in Malvern, Pennsylvania. Its primary product is NeuroStar TMS Therapy System, a non-drug approach to treating major depressive disorder (MDD). This system uses transcranial magnetic stimulation (TMS) to deliver magnetic pulses that stimulate areas of the brain associated with mood regulation. As of April 2025, Neuronetics continues to expand its market presence and refine its technology to better serve patients and healthcare providers.

Neuronetics' core business revolves around the NeuroStar TMS Therapy System. This system is used by psychiatrists and other healthcare professionals to treat adult patients suffering from MDD who have not achieved satisfactory improvement from prior antidepressant medication. The company generates revenue primarily through the sale of NeuroStar systems and the provision of treatment sessions. Additionally, Neuronetics offers service and maintenance agreements for its systems, contributing to recurring revenue. As of April 2025, the company focuses on increasing awareness and adoption of TMS therapy through marketing, education, and ongoing clinical research.

In the fiscal year 2024, Neuronetics reported record-breaking revenue, driven largely by the strong performance of NeuroStar TMS Therapy System sales. The company's total revenue for 2024 reached $86.3 million, an increase of 17% compared to $73.6 million in 2023. This growth was fueled by a 15% increase in U.S. NeuroStar treatment session revenue, which totaled $77.9 million in 2024 versus $67.7 million in the prior year. Capital sales also saw a rise, with 89 systems sold in 2024 compared to 73 systems in 2023. The company has strategically focused on expanding its market reach and improving patient access to TMS therapy, which has contributed significantly to its financial success.

Key financial highlights from the 2024 report include:

• Total revenue of $86.3 million, a 17% increase year-over-year.
• U.S. NeuroStar treatment session revenue increased by 15%, reaching $77.9 million.
• 89 NeuroStar systems were sold, up from 73 in the previous year.
• Gross margin improved to 74.2% compared to 72.5% in 2023.
• Operating expenses totaled $74.9 million, compared to $67.7 million in the prior year.

Neuronetics has established itself as a leader in the neuromodulation industry, particularly in the treatment of depression. Its NeuroStar TMS Therapy System offers a valuable alternative for patients who have not responded well to traditional antidepressant medications. The company's commitment to innovation, clinical research, and patient care has solidified its position in the market. To delve deeper into the company's financial standing and understand the factors driving its performance, check out: Breaking Down Neuronetics, Inc. (STIM) Financial Health: Key Insights for Investors.

Neuronetics, Inc. (STIM) Mission Statement

Neuronetics, Inc. (NASDAQ: STIM) is a commercial-stage medical technology and healthcare company focused on transforming the lives of patients by offering leading neurohealth therapies whenever and wherever they need help. A core belief at Neuronetics is that mental health is as important as physical health, and they demonstrate a patient-centric approach in designing, developing, and marketing their products Exploring Neuronetics, Inc. (STIM) Investor Profile: Who’s Buying and Why?.

The company's mission is centered around renewing lives by transforming neurohealth. They are dedicated to improving the quality of life for individuals suffering from psychiatric disorders through innovative, non-drug, non-invasive treatments.

Neuronetics' commitment extends beyond just providing treatments. The company also cares about practice success, ensuring that healthcare providers have the support and resources needed to offer effective mental health solutions. This commitment is evident in their dedication to ongoing clinical innovation, which aims to create precise, reproducible, and efficient office-based treatment methods for both providers and patients.

As of April 2025, Neuronetics has achieved significant milestones, demonstrating its impact on the mental health landscape:

• Over 195,000 patients treated with NeuroStar
• More than 7.1 million treatment sessions performed

The company's dedication to transforming lives is reflected in its recent financial and operational highlights. In the third quarter of 2024, Neuronetics reported revenue of $18.5 million, a 4% increase compared to the same period in 2023. Additionally, U.S. NeuroStar Advanced Therapy system revenue reached $4.1 million during the same quarter.

Neuronetics' NeuroStar Advanced Therapy System is FDA-cleared for treating adults with Major Depressive Disorder (MDD), as an adjunct treatment for adults with Obsessive-Compulsive Disorder (OCD), and for decreasing anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). It is also cleared as a first-line adjunct treatment for MDD in adolescent patients aged 15-21.

In January 2025, Neuronetics provided business updates and issued financial guidance for 2025, projecting total revenue between $145.0 million and $155.0 million, reflecting a 12% to 19% increase on a pro forma basis. The company also anticipates achieving cash flow breakeven during the third quarter of 2025.

The company's commitment to innovation is highlighted by the FDA clearance of NeuroStar as a first-line adjunct treatment for adolescents with MDD. This clearance was supported by real-world data from the company's TrakStar database, which showed that 78% of adolescent patients treated with NeuroStar achieved clinically meaningful improvement in their depression severity.

Neuronetics' mission is further supported by its core values, which include:

• Passion for Purpose: Inspired by transforming lives, which is central to their work.
• Ethics & Integrity: Committing to doing the right things for the right reasons.
• Teamwork: Succeeding through collaboration and recognizing the power of unity.
• Respect: Seeking to understand and be understood through active engagement.
• Fearlessness: Inspiring transformation through curiosity, challenging norms, and strategic risk-taking.

Neuronetics' vision is to achieve neurohealth for people everywhere. This vision is supported by their mission to renew lives by transforming neurohealth, their patient-centric approach, and their commitment to innovation and clinical excellence.

Neuronetics, Inc. (STIM) Vision Statement of

Neuronetics, Inc. operates with a clear vision focused on transforming the lives of patients suffering from neurological and psychiatric disorders. This vision is supported by a mission to innovate and deliver effective, non-invasive treatments, and is grounded in core values that prioritize patient well-being, innovation, and integrity. Understanding these elements provides insight into the company’s strategic direction and operational philosophy.

Neuronetics' mission is centered around developing and offering innovative, non-invasive medical devices that improve the quality of life for patients with neurological and psychiatric disorders. The company's focus is on providing treatments that are both effective and accessible, reducing the reliance on traditional pharmaceutical interventions that may carry significant side effects. This commitment is reflected in their flagship product, transcranial magnetic stimulation (TMS) systems, which are used to treat conditions like depression.

• Innovation: Continuously seeking and developing new technologies and treatments.
• Patient-Centric Approach: Prioritizing patient outcomes and quality of life.
• Accessibility: Ensuring that treatments are available to a broad range of patients.

Neuronetics' approach is data-driven, with a strong emphasis on clinical research to validate the efficacy and safety of their products. As of the fiscal year 2024, the company has invested significantly in R&D, allocating approximately $15 million to further refine their TMS technology and explore new applications. This investment underscores their dedication to advancing the field of neurotherapy.

The vision of Neuronetics is to be a leading provider of non-invasive neurostimulation therapies that transform the standard of care for neurological and psychiatric disorders. The company aims to create a future where patients have access to safe, effective, and personalized treatments that enable them to achieve lasting relief and improved mental well-being. This vision extends beyond just treating symptoms; Neuronetics seeks to address the underlying causes of these disorders, promoting long-term recovery and enhanced quality of life.

Key components of Neuronetics' vision include:

• Leadership in Neurostimulation: Establishing themselves as a trusted authority in the field.
• Personalized Treatment: Tailoring therapies to meet the unique needs of each patient.
• Improved Patient Outcomes: Achieving significant and sustainable improvements in mental health.

In line with this vision, Neuronetics reported a 20% increase in the number of treatment sessions administered in 2024 compared to the previous year, indicating a growing acceptance and utilization of their TMS therapy. This growth is supported by strategic partnerships with leading psychiatric clinics and hospitals, expanding the reach of their innovative treatments.

Neuronetics' core values guide its operations and shape its culture. These values reflect the company's commitment to ethical practices, scientific rigor, and patient-centered care.

• Integrity: Upholding the highest standards of honesty and transparency in all interactions.
• Innovation: Fostering a culture of creativity and continuous improvement.
• Collaboration: Working together with healthcare professionals, researchers, and patients to achieve shared goals.
• Patient Well-being: Prioritizing the health and safety of patients above all else.

These values are embedded in the company's day-to-day activities, from product development to customer service. For example, Neuronetics adheres to strict regulatory guidelines and conducts thorough clinical trials to ensure the safety and efficacy of its TMS systems. Furthermore, the company provides comprehensive training and support to healthcare providers, empowering them to deliver the best possible care to their patients.

As of 2024, Neuronetics has maintained a 95% satisfaction rate among patients who have undergone TMS therapy, demonstrating the effectiveness of their patient-centered approach. This high satisfaction rate is a testament to the company's commitment to providing compassionate care and delivering positive outcomes.

To gain more insights into the financial aspects that underpin Neuronetics' mission and vision, explore: Breaking Down Neuronetics, Inc. (STIM) Financial Health: Key Insights for Investors

Neuronetics, Inc. (STIM) Core Values of

Neuronetics, Inc. is dedicated to transforming the lives of individuals with psychiatric and neurological disorders through innovative, non-invasive therapies. The company's commitment extends beyond just providing treatments; it encompasses a holistic approach that values integrity, compassion, and excellence. Neuronetics believes that mental health is as important as physical health and strives to improve the quality of life for those they serve. The company's mission is renewing lives by transforming neurohealth.

Neuronetics' ultimate vision is neurohealth achieved for people everywhere. The company is inspired by the opportunity to transform lives through compassion, innovation, and growth. Exploring Neuronetics, Inc. (STIM) Investor Profile: Who’s Buying and Why?

Passion for Purpose

Neuronetics is driven by a passion for its purpose, which is to transform lives. This passion is at the heart of everything they do and is the reason why employees choose to come to work each day. The company is inspired by transforming lives, making it the core of their daily activities.

Ethics & Integrity

Ethics and integrity are paramount at Neuronetics. The company is committed to always doing the right things, in the right way, and for the right reasons. Neuronetics demands the highest quality from themselves and others in everything they do, with the goal of improving the world.

Teamwork

Teamwork is essential to Neuronetics' success. The company believes that they succeed through collaboration, emphasizing that the power within the company is the power of the collective. Jonathan Goad, who has been with Neuronetics for over eight years, highlights the company's drive to put the customer and their patients first, noting the great teamwork within the field service department.

Fearlessness

Fearlessness is a core value that drives Neuronetics to inspire transformation and positive change. This is achieved through active curiosity, challenging the status quo, taking strategic risks, and unleashing innovation. The company is committed to driving learning, growth, and development every day, never settling for less.

Respect

Respect is a fundamental value at Neuronetics. The company constantly seeks to understand and be understood, recognizing that respect is a two-way street. Through active engagement with each other, Neuronetics aims to shift perspectives and see the bigger picture, leveraging unique differences to do better and be better every day.

Neuronetics reported a net loss of $(43.7) million for the year ended December 31, 2024, compared to a net loss of $(30.189) million for the year ended December 31, 2023. Despite these losses, total revenue increased by $3.6 million, or 5%, from $71.3 million for the year ended December 31, 2023, to $74.9 million for the year ended December 31, 2024.

As of December 31, 2024, cash and cash equivalents totaled $18.5 million, a decrease from $59.7 million as of December 31, 2023. The company's adjusted EBITDA for the full year 2024 was $(21.4) million, compared to $(21.0) million for the full year 2023.

In the first quarter of 2024, Neuronetics reported revenue of $17.4 million, a 12% increase compared to the first quarter of 2023. U.S. treatment session revenue increased by 22%, while U.S. NeuroStar Advanced Therapy system revenue was $3.3 million, with 41 systems shipped.

Neuronetics believes that mental health is as important as physical health. The company takes a patient-centric approach to designing, developing, and marketing products that improve the quality of life for people who suffer from psychiatric disorders.